Systemic scleroderma is a systemic autoimmune disease characterized by localized or diffuse skin thickening and fibrosis. The lesions were characterized by fibrous hyperplasia and onion like changes in blood vessels, which eventually led to skin sclerosis and vascular ischemia. This disease is characterized by localized or diffuse skin thickening and fibrosis. In addition to skin involvement, it can also affect visceral organs (such as heart, lung and digestive tract). As an autoimmune disease, it is often accompanied by autoantibodies such as antinuclear antibody, anti centromere antibody and anti ScL-70. The incidence rate of this disease is more than 4 times that of men, and children are relatively rare.
This report contains market size and forecasts of Systemic Scleroderma Treatment in Global, including the following market information:
Global Systemic Scleroderma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Systemic Scleroderma Treatment market was valued at 1604.4 million in 2021 and is projected to reach US$ 2149.7 million by 2028, at a CAGR of 4.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immunosuppressors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Systemic Scleroderma Treatment include Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc. and Bayer AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Systemic Scleroderma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Systemic Scleroderma Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Systemic Scleroderma Treatment Market Segment Percentages, by Type, 2021 (%)
Immunosuppressors
Phosphodiesterase 5 inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Others
Global Systemic Scleroderma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Systemic Scleroderma Treatment Market Segment Percentages, by Application, 2021 (%)
Skin
Bones and Joints
Digestive System
Lung
Heart
Kidney
Global Systemic Scleroderma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Systemic Scleroderma Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Systemic Scleroderma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Systemic Scleroderma Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Bayer AG